Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system

Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab

(2015) NS Vermeer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

(2015) C. Moreno et al.   HAEMATOLOGICA

Progressive Multifocal Leukoencephalopathy Associated with Belimumab in a Patient with Systemic Lupus Erythematosus

(2015) C. LEBLANC-TRUDEAU et al.   JOURNAL OF RHEUMATOLOGY

Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis

(2015) Dominic Borie et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

(2015) C. Moreno et al.   HAEMATOLOGICA

Progressive multifocal leukoencephalopathy: current treatment options and future perspectives

(2015) Dejan Pavlovic et al.   Therapeutic Advances in Neurological Disorders

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab

(2014) Charles L. Bennett et al.   CANCER

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

(2014) Kenneth R. Carson et al.   CANCER

Treating Progressive Multifocal Leukoencephalopathy With Interleukin 7 and Vaccination With JC Virus Capsid Protein VP1

(2014) Mireia Sospedra et al.   CLINICAL INFECTIOUS DISEASES

Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy

(2014) Federico Serana et al.   JOURNAL OF NEUROIMMUNOLOGY

A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab

(2014) CA Fredericks et al.   LUPUS

Treatment of Progressive Multifocal Leukoencephalopathy With Interleukin 7

(2014) Karl B. Alstadhaug et al.   JAMA Neurology

Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era

(2013) J. L. Casado et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs

(2013) Vishvas Garg et al.   Expert Opinion On Drug Safety

PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section

(2013) J. R. Berger et al.   NEUROLOGY

An agenda for UK clinical pharmacology: Pharmacovigilance

(2012) I. Ralph Edwards   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Brentuximab associated progressive multifocal leukoencephalopathy

(2012) Pankaj Jalan et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing

(2012) Monica E. Mazda et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

(2012) Nina D. Wagner-Johnston et al.   LEUKEMIA & LYMPHOMA

Immune reconstitution inflammatory syndrome in natalizumab-associated PML

(2011) I. L. Tan et al.   NEUROLOGY

Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases

(2011) A. Bharat et al.   ARTHRITIS CARE & RESEARCH

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Incidence of progressive multifocal leukoencephalopathy in patients without HIV

(2010) K. L. Amend et al.   NEUROLOGY

Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

(2010) M. Tuccori et al.   ONCOLOGIST

Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

(2009) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents

(2009) Carlo Piccinni et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Progressive Multifocal Leukoencephalopathy Following Heightened Immunosuppression After Lung Transplant

(2009) Jesse Waggoner et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

PML-IRIS in patients with HIV infection: Clinical manifestations and treatment with steroids

(2009) K. Tan et al.   NEUROLOGY

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab

(2009) Werner Wenning et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Immune Reconstitution Associated With Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus

(2008) Jennifer Travis et al.   NEUROLOGIST